Vor Bio
Cambridge, Massachusetts, United States · Biotechnology, Health Care, Other
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide.
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- Unknown
- Industries
- Biotechnology, Health Care, Other
- Status
- Public (VOR)
- Website
- vorbio.com
- Company page
Recent activity at Vor Bio
- : SEC 8-K (5.02): On July 6, 2026, Andrew Levin, M.D., Ph.D. resigned as a Director of Vor Biopharma Inc., effective immediately. His resignation was not due to any disagreement with the Company. Following this, on July 7, 2026, David Zaccardelli, Pharm.D. was appointed as a director, filling the vacancy left by Dr. Levin. Zaccardelli will serve until the 2029 annual stockholders meeting and will receive an annual cash retainer of $40,000 as part of the Company's standard non-employee director compensation. This appointment is significant as Dr. Zaccardelli brings extensive experience from leadership roles in other pharmaceutical companies and may influence the Company’s strategic direction moving forward.
- : SEC 8-K (7.01): On June 8, 2026, Vor Biopharma Inc. disclosed that RemeGen Co., Ltd. received conditional approval from the National Medicinal Products Administration (NMPA) for its drug telitacicept for the treatment of adult patients with IgA nephropathy, and full approval for the same drug for treating adult patients with Sjögren’s disease in China. This approval is critical as it expands the market potential for telitacicept in treating significant renal and autoimmune conditions. The announcement comes with the issuance of press releases, detailed in Exhibits 99.1 and 99.2, highlighting the strategic implications for Vor Biopharma's partnership with RemeGen. This development is expected to enhance growth opportunities and market presence in the Chinese biopharmaceutical landscape.
- : SEC 8-K (1.01): On March 26, 2026, Vor Biopharma Inc. entered into a Securities Purchase Agreement with entities affiliated with TCGX, known as the Investors. The Company agreed to issue and sell an aggregate of 5,338,078 shares of common stock at a price of $14.05 per share, resulting in gross proceeds of approximately $75.0 million. The Private Placement is set to close on March 30, 2026, contingent on customary closing conditions. The proceeds will be utilized to advance the Company's clinical pipeline and for general corporate purposes. Additionally, a Registration Rights Agreement was established, obligating the Company to file a registration statement for the resale of the shares within 30 days post-closing, with specific deadlines and provisions for liquidated damages if these are not met.
- : SEC 8-K (7.01):
- : SEC 8-K (5.02): On December 31, 2025, Vor Biopharma Inc. entered into a separation agreement with Dr. Qing Zuraw, the Chief Development Officer, following his decision to pursue other opportunities. Dr. Zuraw's employment officially ended on the same date, and he will receive severance benefits in accordance with his employment agreement dated July 17, 2025. The separation agreement includes a 12-month non-compete clause, along with non-disparagement and confidentiality covenants. Furthermore, the Company plans to engage Dr. Zuraw as a consultant during the transition period in the first quarter of 2026, ensuring his expertise is utilized effectively during this transition.
- : SEC 8-K (5.02): On December 17, 2025, Sarah Reed resigned from the Company's Board of Directors, effective immediately, with no disagreements cited. In her place, on December 18, 2025, the Board appointed Andrew Levin as an independent Class II director, a position he will hold until the 2026 annual meeting of stockholders. Dr. Levin, who has extensive experience in the life sciences sector, was nominated under a securities purchase agreement dated December 26, 2024. Additionally, Wouter Joustra was appointed as an independent Class III director to serve until the Company's 2027 annual meeting. These appointments are part of the Board's strategy to strengthen leadership and governance, particularly given their respective backgrounds in investment and life sciences.
- : SEC 8-K (5.02):
- : SEC 8-K (8.01): On November 10, 2025, Vor Biopharma Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Jefferies LLC, Citigroup Global Markets Inc., and TD Securities (USA) LLC for an equity offering of 10,000,000 shares of common stock at a price of $10.00 per share. The offering is expected to generate approximately $93.7 million in net proceeds, which will be used for clinical development of telitacicept, including a Phase 3 trial for primary Sjögren’s Disease, and for general corporate purposes. The closing is anticipated to occur on November 12, 2025, pending customary closing conditions. The Underwriters were granted a 30-day option to purchase an additional 1,500,000 shares at the same public price. The agreement includes standard representations and warranties, as well as conditions to closing and indemnification provisions.
- : Vor Biopharma Appoints Dr. Jeremy Sokolove as Chief Medical Officer
- : SEC 8-K (5.02): On November 2, 2025, Vor Biopharma Inc. and Dr. Qing Zuraw, the Company’s Chief Development Officer, entered into an Employment Agreement Amendment which modifies the terms of her severance benefits. The amendment stipulates that if Dr. Zuraw is terminated without cause, she will receive a pro-rated portion of her 2025 and possibly 2026 target bonuses as a lump sum. Additionally, if she resigns after December 31, 2025, she will receive similar severance benefits. The amendment is effective for five months from the Effective Date, signaling a strategic move to enhance retention and compensation stability for key leadership.
Vor Bio funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2020 | Venture | $110.1M |
| Jul 2020 | Series B | $110.0M |
Leadership
- Robert Ang, Executive Officer, Director
- Joshua Resnick, Director
- Sven Lundberg, Director
- Kush Parmar, Director
- Jeremy Sokolove, Chief Medical Officer
- Jean-Paul Kress, Chief Executive Officer
- Sherell Bacchas, Senior Vice President of Finance
- Amy Mendel, Executive Officer
- Nathan Jorgensen, Executive Officer
Verified email and direct lines for Vor Bio’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Vor Bio files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Vor Bio in the news
- Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference - Yahoo Finance (Feb 23, 2026)
- Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions - Fierce Pharma (Jun 26, 2025)
- Vor Bio to wind down, halting cell therapy trials and shedding most staff - Fierce Biotech (May 08, 2025)
- Vor Bio To Participate in Upcoming September Conferences - GlobeNewswire (Sep 01, 2026)
- Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire (Aug 11, 2026)
- Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD - GlobeNewswire (Mar 30, 2026)
- Vor Bio Announces $175 Million Private Placement - GlobeNewswire (Jun 25, 2025)
- Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset - GlobeNewswire (Jun 25, 2025)
Companies similar to Vor Bio
- Valitor · Biotechnology, Health Care, Other, Therapeutics
- Ajax Therapeutics, Inc. · Biotechnology, Health Care, Other, Therapeutics
- Strata Oncology · Biotechnology, Health Care, Other, Therapeutics
- Gallant · Biotechnology, Health Care, Other, Therapeutics
- Centaurus Therapeutics · Biotechnology, Health Care, Other, Therapeutics
About Vor Bio: questions and answers
What does Vor Bio do?
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide.
Where is Vor Bio headquartered?
Vor Bio is headquartered in Cambridge, Massachusetts, United States.
Has Vor Bio raised funding?
Yes. Fundz has recorded 2 funding events for Vor Bio. The most recent, $110.1M, was in Jul 2020.
Who leads Vor Bio?
Jean-Paul Kress is a Chief Executive Officer at Vor Bio.
What is the latest news on Vor Bio?
On Jul 07, 2026, SEC 8-K (5.02): On July 6, 2026, Andrew Levin, M.D., Ph.D. resigned as a Director of Vor Biopharma Inc., effective immediately. His resignation was not due to any disagreement with the Company. Following this, on July 7, 2026, David Zaccardelli, Pharm.D. was appointed as a director, filling the vaca
Is Vor Bio a public company?
Yes. Vor Bio is publicly traded under the ticker VOR.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy